Onatasertib is a small molecule commercialized by Antengene, with a leading Phase I program in Follicular Lymphoma. According to Globaldata, it is involved in 14 clinical trials, of which 6 were completed, 6 are ongoing, 1 is planned, and 1 was terminated. GlobalData uses proprietary data and analytics to provide a complete picture of Onatasertib’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for Onatasertib is expected to reach an annual total of $25 mn by 2033 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Onatasertib (CC-223) is under development for the treatment of advanced refractory solid tumors including hepatocellular carcinoma, relapsed/refractory diffuse large B-cell lymphoma, non-small cell lung carcinoma, esophageal squamous cell carcinoma, gastric cancer, follicular lymphoma, non-. The drug candidate is administered orally. The drug candidate targets the mammalian target of rapamycin complex (mTOR). It was under development for the treatment of neuroendocrine tumors, Hodgkin lymphoma and multiple myeloma, non-small cell lung cancer and prostate cancer, colon cancer, glioma, breast cancer
Antengene is a biopharmaceutical company that discovers and develops oncology medicines. The company is investigating ATG-010, a first-in-class SINE compound targeting XPO1 molecule, to treat multiple myeloma and diffuse large B-cell lymphoma; ATG-008, an mTOR kinase inhibitor for the treatment of solid tumors and hematological malignancies; ATG-016 targeting KRAS-mutant solid tumors and nasopharyngeal carcinoma; ATG-527 against viral infection; ATG-019, oral inhibitor for solid tumors; ATG-017, signal- regulated kinases 1 and 2 (ERK1/2) inhibitor solid tumors, non-Hodgkin lymphoma, acute myeloid leukemia. It is also evaluating drugs against solid tumors, hematology, and oncology indications. The company has additional office in Shaoxing, Zhejiang, China; and operational presence in Hong Kong and the US. Antengene is headquartered in Shanghai, China.
The company reported revenues of (Renminbi) CNY28.8 million for the fiscal year ended December 2021 (FY2021). The operating loss of the company was CNY654.8 million in FY2021, compared to an operating loss of CNY2,927.9 million in FY2020. The net loss of the company was CNY655.5 million in FY2021, compared to a net loss of CNY2,928.9 million in FY2020.
For a complete picture of Onatasertib’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.
#current #valuation #Antengenes #Onatasertib